The investigation for suspected allergic rhinitis included a detailed clinical history, a physical examination and use of in-vivo or vitro testing to determine the allergens that provocating the symptoms. Among the diagnosis of allergic rhinitis, the skin test is a useful diagnostic test to document the specific IgE reactivity, but some patients cannot be performed. So in such a patients, in-vitro test has been advocated as a method for measuring allergen specific IgE antibodies. Recently, newly developed fluoroenzyme immunoassay(CAP system) has been used. The CAP system is new assay for serum specific IgE characterized by a new solid phase (hydrophilic polymer encased in a capsule), utilizing a solid phase capable of binding more antigen than conventional methods, and proved to be simpler, safer, faster, easier, more specific, and more sensitive than conventional method. The CAP results were compared to those of the skin prick test performed in 228 subjects with 13 common inhalant allergens. Total agreement rate of 13 allergens between skin prick test and CAP system was 63.1%, each agreement rates were 86.8% in D. pteronyssinus, 85.5% in D. farinae, 19.4% in Cat epithelium, 15.1% in Dog dander, 71.4% in Cockroach, 80.4% in Alder, 81.0% in Birch, 79.4% in Hazel, 74.2% in Oak, 82.1% in Beech, 69.2% in Mugwort, 39.0% in Chrysanthemum, 29.3% in Ragweed(Table 16). These results suggested that the CAP system is a clinically useful assay for specific IgE and appears to be a clear advancement for invitro tests technology.